Most Popular Angioplasty Web Site
supported by Volcano Corporation
Volcano Announces the Availability of Integrated Fractional Flow Reserve Technology on All Major Cardiovascular X-ray Angiography Systems
Availability Builds on the Success of the Expanding s5i Integrated Platform

Franctional Flow Reserve
Doppler Guide Wire,
measuring FFR inside
coronary artery
image courtesy of
Volcano Corporation

March 27, 2009 -- San Diego -- Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, today announced the availability of its integrated Fractional Flow Reserve (FFR) technology on all major cardiovascular x-ray systems.

Interest in the use of FFR, a guidewire-based technology that helps assess a lesion's severity, has increased significantly since the release of the multi-center randomized FAME (FFR versus Angiography for Multivessel Evaluation) data in late 2008 and publication in the New England Journal of Medicine in January 2009.

FAME demonstrated that FFR-guidance in routine multi-vessel PCI resulted in clinically-superior outcomes and reduced the composite of death, documented myocardial infarction, and repeat revascularization by 30 percent at one year. The study also demonstrated that these improved clinical outcomes were complemented by significantly reduced cost to the hospitals involved in the trial.

Volcano's integrated FFR technology can be purchased as part of Volcano's s5i system, offering clinicians access to IVUS and FFR at the patient bedside. Volcano has relationships with each of the major cardiovascular x-ray companies to facilitate the installation of the s5i with integrated FFR in any cath lab.

Joe Burnett, Vice President of Marketing at Volcano commented, "As demonstrated by Volcano's FFR growth of 36 percent in Q4 2008 versus Q4 2007, physicians are increasingly relying on FFR to help guide PCI procedures turning to Volcano's s5i system as their preferred FFR solution. We are pleased to offer customers the ability to have integrated FFR in their lab, regardless of the x-ray system that they use."

Volcano's integrated s5i will be on display at the 2009 ACC meeting in Orlando at the company's booth as well as in the booths of GE, Philips, Siemens and Toshiba.

About Volcano
Volcano Corporation (Nasdaq: VOLC) offers a broad suite of devices designed to facilitate endovascular procedures, enhance the diagnosis of vascular and structural heart disease and guide optimal therapies. The company's intravascular ultrasound (IVUS) product line includes ultrasound consoles that can be integrated directly into virtually any modern cath lab. Volcano IVUS offers unique features, including both single-use phased array and rotational IVUS imaging catheters, and advanced functionality options, such as VH® IVUS tissue characterization and ChromaFlo®. Volcano also provides functional measurement (FM) consoles and single-use pressure and flow guide wires and is developing a line of ultra-high resolution Optical Coherence Tomography (OCT) and Forward Looking IVUS systems and catheters. Currently, more than 4,000 Volcano IVUS and FM systems are installed worldwide, with approximately half of its revenues coming from outside the United States. For more information, visit the company's website at

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release regarding Volcano's business that are not historical facts may be considered "forward-looking statements," including statements regarding the company's financial guidance for 2009, market adoption of the company's technology, the impact of clinical and other technical data, the success and timing of product development, product introduction and clinical trial programs, growth strategies and market development and product sales. Forward-looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties, which may cause Volcano's results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from the results predicted are detailed in the company's annual report on Form 10-K, quarterly reports on Form 10-Q and other filings made with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Volcano undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Source: Volcano Corporation